AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

 AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

Shots:

  • AZ will receive an upfront $700M & $115M plus milestone payments up to $90M & $17M for Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) respectively. Grunenthal to get commercialization rights for Nexium in EU & WW rights for Vimovo (except in the US & Japan)
  • AZ will continue to manufacture and supply Nexium under the long-term supply agreement having its global commercialization rights except in EU
  • Nexium a proton pump inhibitor indicated for gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome & Vimovo is a FD combination drug of naproxen, for OA, RA & AS having net sales $121M in EU & $37M WW (except the US & Japan) respectively
  • In 2012 & 2013, Pfizer Consumer Health & Horizon Pharma gained rights for Nexium (over-the-counter) & Vimovo (in the US) from AZ respectively

Click here to read full press release/ article | Ref: AstraZeneca| Image: Pharmacy Business

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post